Lupin sells U.S. Commercial Women’s Health Specialty Business to Evofem

Lupin announced it has divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences. Lupin’s U.S. Commercial Women’s Health Specialty Business is primarily focused on commercializing SOLOSEC 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis and trichomoniasis, two common sexual health infections. Under the terms of the deal, Lupin can receive a potential total consideration of up to $84M based on future contingent milestones.